Risankizumab Safe, Effective in Moderate to Severe Crohn's Disease - Medpage Today

Risankizumab Safe, Effective in Moderate to Severe Crohn's Disease - Medpage TodayПодробнее

Superior risankizumab efficacy vs. apremilast in systemic-eligible moderate psoriasis.Подробнее

Brian Feagan, MD: Risankizumab for Crohn's DiseaseПодробнее

Crohn’s Disease and Endoscopic Improvement | See Abbv.ie/SkyriziPIПодробнее

Antibiotic Reverses Cognition Loss in MHEПодробнее

Amongst people w/ psoriasis, does exposure to Risankizumab ... (Yiu, SOS Challenge Presentation)Подробнее

FDA approves Rinvoq as first pill to treat moderate-to-severe Crohn's DiseaseПодробнее

Ken Gordon, MD: Insights on Risankizumab for Plaque PsoriasisПодробнее

Role of Placebo in the UltIMMa Trials - Medpage TodayПодробнее

Ken Gordon, MD: Clinical Implications of the UltIMMa Trials of RisankizumabПодробнее

If you take Skyrizi pls lmk! #skyrizi #psoriasis #psoriaticarthritis #psoriasistreatmentПодробнее

Crohn's DiseaseПодробнее

Risankizumab worsened symptoms in patients with severe asthma, new study findsПодробнее

Will Cannabis Cure Crohn's?Подробнее

Study shows risankizumab is effective regardless of prior biologic treatmentПодробнее

Risankizumab for PsA: How will the KEEPsAKE 1 & 2 findings impact clinical practice? | Laura CoatesПодробнее

Risankizumab impresses in phase 2 psoriatic arthritis trialПодробнее

Risankizumab shows promise for PsA in the KEEPsAKE 2 trial | Andrew OstorПодробнее

Uses & Important Safety Info | See Bit.ly/SkyriziPIПодробнее

New Crohn Disease Clinical Trial: Ozanimod for Crohn DiseaseПодробнее